维奈克拉治疗慢性淋巴细胞白血病中肿瘤溶解综合征的真实世界发生率与预防
本研究回顾性分析本机构2016年1月1日至2020年12月31日期间136例慢性淋巴细胞白血病(CLL)患者接受维奈克拉递增治疗的616次递增事件,实验室肿瘤溶解综合征(TLS)发生率为5.1%,无临床TLS发生;仅住院递增者实验室TLS发生率为15%,任何预防性住院者为2.9%,仅门诊递增者为2.7%。
要点
- 136例CLL患者共616次维奈克拉递增,实验室TLS发生率5.1%,无临床TLS发生。
- 仅住院递增者实验室TLS发生率为15%,任何预防性住院者为2.9%,仅门诊递增者为2.7%。
- 发生TLS者更可能有较高TLS风险,未发现其他额外风险因素。
核心结论
- 在本单机构回顾性队列研究中,观察到实验室TLS发生,但未发生临床TLS。
- 预防措施包括静脉水化可能有助于门诊环境下观察到的低TLS发生率。
研究设计与样本
- 单机构回顾性队列研究,纳入本机构2016年1月1日至2020年12月31日期间接受维奈克拉治疗的CLL/小淋巴细胞淋巴瘤患者。
- 共纳入136例CLL患者的616次维奈克拉递增。
主要发现
- 74例患者(54%)仅门诊递增,35例(26%)至少1次计划住院,27例(20%)仅住院递增。
- 维奈克拉启动期间,86%患者接受别嘌醇,71%接受静脉水化,18%接受磷酸盐结合剂,10%接受预防性拉布立酶。
- 整个队列中7例患者(5.1%)按改良Cairo Bishop标准发生实验室TLS,无临床TLS发生。
- 仅住院递增者实验室TLS发生率为15%,任何预防性住院者为2.9%,仅门诊递增者为2.7%。
- 发生TLS者更可能有较高TLS风险,未发现其他额外风险因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax is a B-cell lymphoma 2 inhibitor used in chronic lymphocytic leukemia (CLL), which can cause tumor lysis syndrome (TLS). We aimed to determine the incidence of, and risk factors for, TLS among patients with CLL/small lymphocytic lymphoma who received treatment with venetoclax at our institution from 1 January 2016 to 31 December 2020. We included 616 venetoclax escalations among 136 patients with CLL. Overall, 74 patients (54%) underwent escalation exclusively outpatient, 35 (26%) had at least 1 planned hospitalization, and 27 (20%) were escalated exclusively inpatient. During venetoclax initiation, 86% of patients received allopurinol, 71% intravenous hydration, 18% phosphate binders, and 10% prophylactic rasburicase. Among the entire cohort, 7 patients (5.1%) developed laboratory TLS by modified Cairo Bishop criteria and none developed clinical TLS. Incidence of laboratory TLS was 15% for those escalated exclusively inpatient, 2.9% for those with any prophylactic hospitalization, and 2.7% for those escalated exclusively outpatient. Those who developed TLS were more likely to have higher TLS risk, and no additional risk factors were identified. In this single institution retrospective cohort study, laboratory TLS was observed, although clinical TLS was not. Prophylactic measures, including use of IV hydration, may have contributed to low rates of observed TLS in the outpatient setting.
引用
- Valtis YK, Nemirovsky D, Derkach A, et al. Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax. Blood Adv. 2024. PMID: 39121368. doi:10.1182/bloodadvances.2024013927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。